



Novel Antioxidant Nanozymes for Biomedical Applications

Anton D. Aleksashkin¹, Natalia V. Nukolova^{1,2}, Vladimir P. Chekhonin^{2,3}, Natalia L. Klyachko¹, Alexander V. Kabanov^{1,4}

¹Lomonosov Moscow State University

²The Serbsky State Scientific Center for Social and Forensic Psychiatry


³Pirogov Russian National Research Medical University

⁴University of North Carolina at Chapel Hill


E-mail: AntonD.Aleksashkin@gmail.com



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL




Human superoxide dismutase (SOD1)



Catalase protein structure



in vivo experiments




Rat spinal cord injury model was used to evaluate therapeutic efficiency of samples. Last were injected 30 minutes after injury. BBB-test and MRI were used to estimate recovery of rats. NZ2 show great therapeutic effect.




Diffusion tensor imaging was used to estimate recovery of spinal cord pathways. Blue color means normal neuronal conductivity; red – disturbed.

Pharmacokinetic experiments



Pharmacokinetic (PK) experiments were performed on healthy Sprague Dawley rats. Equal concentrations in terms of activity were injected intravenously. SOD activity in plasma was measured with indirect enzymatic assay. NZ2 show remarkably better PK profile with enhanced $t_{1/2}$ and AUC.


in vitro experiments



Confocal microscopy was used to investigate samples stability and internalization. HEK293 cells were incubated with samples for 30 minutes. SOD internalizes in cells while PLL-PEG is localized on membranes. NZ1 release enzyme which internalizes; polymer is on membranes. NZ2 do not release enzyme and colocalization is observed.

MTT-assay was used to evaluate cytotoxicity. Samples were incubated with HEK293 cells during 24 hours. Notably, non-toxic concentrations were used for all *in vivo* experiments.

Physico-chemical characterization



Sample	Protein yield, %	Specific activity, %	Total activity, %	Hydro-dynamic diameter, nm	PdI
BIC	25±3	16±2	4±2	30±2	0.12
NZ1	28±2	15±7	5±3	30±3	0.21
NZ2	60±5	58±6	35±4	40±4	0.15

Release of enzyme from particles is crucial parameter for PK profile and therapeutic efficiency. Second layer of polymer in NZ2 allows us to use more reactive linker with no loss in activity. Such particles (NZ2) retain enzyme inside better than NZ1 and BIC. This also leads to greater protein yield and specific activity.

Conclusions

- ✓ Drug delivery system for antioxidant enzymes was developed.
- ✓ Second layer of polymer defends active site of enzyme during modification and allows us to use more active linker.
- ✓ Use of glutaraldehyde remarkably improves pharmacokinetics profile and, therefore, therapeutic efficiency of nanozymes.

This work was supported by Grant of Russian Federation government 11G34.31.0004 from 11.30.2010 and by grant from Foundation for assistance to small innovative enterprises in science and technology under the program "UMNIK".